These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36043937)

  • 1. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom.
    Otero-Losada M; Petrovsky N; Alami A; Crispo JA; Mattison D; Capani F; Goetz C; Krewski D; Perez-Lloret S
    Expert Opin Drug Saf; 2023 Apr; 22(4):343-349. PubMed ID: 36043937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan.
    Abdel-Qader DH; Abdel-Qader H; Silverthorne J; Kongkaew C; Al Meslamani AZ; Hayajneh W; Ata OMA; Shnaigat W; AbuRuz S; Al Nsour M; Alhariri A; Shnewer K; Da'ssan M; Obeidat NM; Nusair KE; Jalamdeh MS; Hawari F; Khader K; Hakim T; Hammad FA; Al Qudah M; Asad M
    Clin Drug Investig; 2022 Oct; 42(10):813-827. PubMed ID: 35999428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform.
    Walker JL; Schultze A; Tazare J; Tamborska A; Singh B; Donegan K; Stowe J; Morton CE; Hulme WJ; Curtis HJ; Williamson EJ; Mehrkar A; Eggo RM; Rentsch CT; Mathur R; Bacon S; Walker AJ; Davy S; Evans D; Inglesby P; Hickman G; MacKenna B; Tomlinson L; Ca Green A; Fisher L; Cockburn J; Parry J; Hester F; Harper S; Bates C; Evans SJ; Solomon T; Andrews NJ; Douglas IJ; Goldacre B; Smeeth L; McDonald HI
    Vaccine; 2022 Jul; 40(32):4479-4487. PubMed ID: 35715350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
    Kim JE; Park J; Min YG; Hong YH; Song TJ
    J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature.
    Eslait-Olaciregui S; Llinás-Caballero K; Patiño-Manjarrés D; Urbina-Ariza T; Cediel-Becerra JF; Domínguez-Domínguez CA
    Ther Adv Drug Saf; 2023; 14():20420986231165674. PubMed ID: 37223456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review.
    Mahroum N; Lavine N; Ohayon A; Seida R; Alwani A; Alrais M; Zoubi M; Bragazzi NL
    Front Immunol; 2022; 13():872683. PubMed ID: 35865539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing adverse events following COVID-19 vaccination.
    Villanueva P; McDonald E; Croda J; Croda MG; Dalcolmo M; Dos Santos G; Jardim B; Lacerda M; Lynn DJ; Marshall H; Oliveira RD; Rocha J; Sawka A; Val F; Pittet LF; Messina NL; Curtis N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2323853. PubMed ID: 38445666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study.
    Aldali J; Meo SA; Al-Khlaiwi T
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.
    Sharif N; Opu RR; Saha T; Khan A; Aljohani A; Alsuwat MA; García CO; Vázquez AA; Alzahrani KJ; Miramontes-González JP; Dey SK
    Sci Rep; 2024 Oct; 14(1):23794. PubMed ID: 39394252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Immediate Allergic Reactions After Immunization With the Pfizer BNT162b2 Vaccine Using Intradermal Skin Testing With the COVID-19 Vaccines.
    Shavit R; Maoz-Segal R; Offengenden I; Yahia SH; Maayan DM; Lifshitz Y; Niznik S; Deutch M; Elbaz E; Genaim H; Iancovici-Kidon M; Agmon-Levin N
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2677-2684. PubMed ID: 35973526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post COVID-19 vaccination: AusVaxSafety survey participation and adverse events - a community-based regional Queensland study.
    Hamilton E; Oversby S; Kitchener S; Ratsch A
    Aust N Z J Public Health; 2022 Dec; 46(6):738-744. PubMed ID: 36190203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
    Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
    Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
    BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland.
    Paczkowska A; Hoffmann K; Michalak M; Hans-Wytrychowska A; Bryl W; Kopciuch D; Zaprutko T; Ratajczak P; Nowakowska E; Kus K
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort.
    Joy M; Agrawal U; Fan X; Robertson C; Anand SN; Ordonez-Mena J; Byford R; Goudie R; Jamie G; Kar D; Williams J; Marsden GL; Tzortziou-Brown V; Sheikh SA; Hobbs FDR; de Lusignan S
    Lancet Reg Health Eur; 2023 Sep; 32():100681. PubMed ID: 37671127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.
    Li Y; Li J; Dang Y; Chen Y; Tao C
    JMIR Public Health Surveill; 2024 Jul; 10():e51007. PubMed ID: 39008362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.